Literature DB >> 10613750

Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study.

L Fanning1, E Kenny-Walsh, J Levis, K R Choudhury, B Cannon, M Sheehan, M Whelton, F Shanahan.   

Abstract

The aim of this study was to determine the variation in hepatitis C viral load over an extended period of patient follow up. Serum samples were collected from 49 female individuals who were identified as having been infected from the same source of hepatitis C-contaminated anti-D immunoglobulin during the period from 1977 (May) to 1978 (November). All patients attended the hepatitis C clinic at Cork University Hospital, Cork, Ireland. The study group was homogeneous with respect to gender, hepatitis C virus (HCV) genotype (1b), and duration of infection. None of the patients had received antiviral therapy at the time of completion of study. Viral load quantifications were assessed using the Roche Monitor (F. Hoffmann-La Roche, Ltd., Basel, Switzerland) assay. The mean age of the study group at time of infection was 30.3 years (SD +/- 6.1) with a range from 18.5 to 43 years. The mean time of follow-up was 4. 1 years (SD +/- 1.0) with a range from 1.2 to 5 years. The mean rate of change of viral load per year was 0.23 log(10) viral copies per mL serum for the study group (SD +/- 0.19) with a range of -0.18 to 0.78 that was significantly different from zero, P < 10(-10). The rate of change of viral load per year was negatively correlated with viral load at first determination, r = -.35, P =.01. Age at infection did not correlate with the slope of change of viral load, P =.10. In conclusion, most women infected with HCV 1b will have an increase in viral load over time but a few patients who acquire infection early in adult life will show a decrease in viral load.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10613750     DOI: 10.1002/hep.510310133

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

Review 1.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

2.  Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests.

Authors:  F S Nolte; M W Fried; M L Shiffman; A Ferreira-Gonzalez; C T Garrett; E R Schiff; S J Polyak; D R Gretch
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

3.  Comparison of serial Hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation.

Authors:  Howard B Gale; D Robert Dufour; Nazia N Qazi; Virginia L Kan
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

4.  Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C.

Authors:  Hernando J Gonzalez; Samuel B Ho; John B Gross; Craig Peine; Daniel McKee; Theresa Smith
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

5.  Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis.

Authors:  John R Ticehurst; Fayez M Hamzeh; David L Thomas
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

Review 6.  Acute hepatitis C: management in the rapidly evolving world of HCV.

Authors:  Suraj A Sharma; Jordan J Feld
Journal:  Curr Gastroenterol Rep       Date:  2014-02

Review 7.  Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.

Authors:  Ozan Yazici; Mehmet Ali Nahit Sendur; Sercan Aksoy
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

8.  Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria.

Authors:  Barbara H McGovern; Christopher E Birch; Melinda J Bowen; Laura L Reyor; Ellen H Nagami; Raymond T Chung; Arthur Y Kim
Journal:  Clin Infect Dis       Date:  2009-10-01       Impact factor: 9.079

9.  Reactivation of Chronic Hepatitis C as a Potential Trigger for Guillain-Barré Syndrome.

Authors:  Ogochukwu Molokwu; Brittany M Young; Manjit Singh; Krishe Menezes; Raza Mian
Journal:  Cureus       Date:  2019-07-26

10.  Suppression of hepatitis C virus replication during COVID-19 infection.

Authors:  Tyng-Yuan Jang
Journal:  Kaohsiung J Med Sci       Date:  2022-01-20       Impact factor: 2.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.